Skip to main content
Signal8
Launch Terminal

SINOVAC BIOTECH LTD (SVA)

Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella vaccine; a pneumococcal polysaccharide vaccine designed to prevent Streptococcus pneumoniae infections like pneumonia and septicemia; a quadrivalent influenza vaccine providing defense against two influenza A and two influenza B viruses; and CoronaVac, its vaccine developed to address COVID-19. Additionally, Sinovac's development pipeline features a sabin inactivated polio vaccine, which has concluded Phase III clinical trials for poliomyelitis treatment, alongside a rubella vaccine candidate. The company has established several collaboration agreements, including with GlaxoSmithKline Biologicals SA for the development of measles-containing combination vaccines for the Chinese market; with Tianjin CanSino Biotechnology Inc. to advance a pneumococcal vaccine; and with Instituto Butantan to progress the Phase III clinical trials of CoronaVac, its inactivated COVID-19 vaccine candidate. Sinovac Biotech Ltd. was established in 1993 and maintains its principal offices in Beijing, China.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Sinovac Biotech Ltd. logo

Sinovac Biotech Ltd.

NASDAQ:SVAHealthcare
Mkt Cap-
Float18.45M
O/S-
Vol
$ Vol
RVOL
Inst Own-
SI0.5%
Earnings
Dilution
Sinovac Biotech Ltd. logoNASDAQ:SVAHalted T12
Phase Distribution
115 lead-sponsored trials·11 active·81 completed
Phase 19
Phase 1/26
Phase 28
Phase 333
Phase 444
Not applicable15
(3 more as collaborator)
Status Overview
Not yet recruiting9
Recruiting9
Active, not recruiting2
Completed81
Stopped5
Unknown9

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine

    Healive® Lot 1, Healive® Lot 2

    Hepatitis A

    Enrollment
    400
    Start
    Mar 2006
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT00534885
  • Phase 4
    Completed

    Phase IV Clinical Trial of an Influenza Split Vaccine Anflu

    seasonal split influenza vaccine, seasonal split influenza vaccine

    Influenza

    Enrollment
    566
    Start
    Sep 2007
    Primary Completion
    -
    Completion
    Nov 2007
    NCT00556062
  • Phase 4
    Completed

    A Clinical Trial With Influenza A/H1N1 Vaccines

    split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose, split-virion, adjuvanted H1N1 vaccine of 15 μg per dose

    Influenza

    Enrollment
    1,614
    Start
    Jul 2009
    Primary Completion
    Sep 2009
    Completion
    Oct 2009
    NCT00956111
  • Phase 4
    Completed

    A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

    H1N1 influenza A Vaccine (Split virion), Inactivated

    Influenza

    Enrollment
    100
    Start
    Sep 2009
    Primary Completion
    Oct 2009
    Completion
    Nov 2009
    NCT01004653
  • Phase 4
    Completed

    Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

    H1N1 influenza A Vaccine (PANFLU.1), Trivalent Inactivated Influenza Vaccine (ANFLU)

    Influenza

    Enrollment
    150
    Start
    Oct 2009
    Primary Completion
    Dec 2009
    Completion
    Jan 2010
    NCT01008137
  • Phase 4
    Completed

    Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

    Pandemic influenza A/H1N1 vaccine, Pandemic influenza A/H1N1 vaccine

    Influenza

    Enrollment
    310
    Start
    Dec 2009
    Primary Completion
    Mar 2010
    Completion
    May 2010
    NCT01047202
  • Phase 4
    Completed

    Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines

    Healive+Healive, Healive+Havrix

    Hepatitis A

    Enrollment
    303
    Start
    Apr 2010
    Primary Completion
    Feb 2011
    Completion
    May 2011
    NCT01252680
  • Phase 4
    Completed

    The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine

    2012-2013 trivalent seasonal influenza vaccine

    Influenza

    Enrollment
    202
    Start
    Nov 2012
    Primary Completion
    Apr 2013
    Completion
    May 2013
    NCT01736709
  • Phase 4
    Completed

    Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults

    Inactivated HAV vaccine, Live attenuated HAV vaccine

    Hepatitis A

    Enrollment
    239
    Start
    Oct 2008
    Primary Completion
    Dec 2011
    Completion
    Sep 2012
    NCT01865968
  • Phase 4
    Completed

    The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

    trivalent seasonal influenza vaccine

    Influenza

    Enrollment
    182
    Start
    Dec 2013
    Primary Completion
    Apr 2014
    Completion
    Jun 2014
    NCT02269852
  • Phase 4
    Completed

    Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine

    Inactivated Hepatitis A vaccine (HAV), Combined hepatitis A and hepatitis B vaccine (HABV)

    Hepatitis A, Hepatitis B

    Enrollment
    301
    Start
    May 2014
    Primary Completion
    Jan 2015
    Completion
    Jun 2016
    NCT02445703
  • Phase 4
    Completed

    Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

    Concomitant administration of EV71 vaccine with EPI vaccines, Single injection of EPI vaccine

    Hand, Foot and Mouth Disease

    Enrollment
    780
    Start
    Apr 2017
    Primary Completion
    Nov 2017
    Completion
    Nov 2017
    NCT03274102
  • Phase 4
    Completed

    Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

    EV71 vaccine

    Hand, Foot and Mouth Disease

    Enrollment
    120
    Start
    Jul 2017
    Primary Completion
    Sep 2017
    Completion
    Sep 2017
    NCT03278132
  • Phase 4
    Completed

    Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

    EV71 inactived vaccine（Vero cells）, EV71 inactived vaccine（Human diploid cells）

    Hand, Foot and Mouth Disease

    Enrollment
    300
    Start
    Nov 2018
    Primary Completion
    Jan 2019
    Completion
    Jan 2019
    NCT03873740
  • Phase 4
    Completed

    Efficacy Trial of a Commercial EV71 Vaccine

    5000 volunteers (6-35 months)-EV71 vaccine

    Hand, Foot and Mouth Disease

    Enrollment
    15,500
    Start
    Mar 2019
    Primary Completion
    Jun 2020
    Completion
    Oct 2020
    NCT03903926
  • Phase 4
    Completed

    Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

    Concomitant administration of EV71vaccine with EPI vaccines, Single injection of EPI vaccine

    Hand, Foot and Mouth Disease

    Enrollment
    372
    Start
    Jul 2019
    Primary Completion
    Nov 2019
    Completion
    Mar 2020
    NCT04111432
  • Phase 4
    Completed

    Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

    Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.

    COVID-19, Influenza

    Enrollment
    480
    Start
    Mar 2021
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04801888
  • Phase 4
    Completed

    Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

    Inactivated SARS-CoV-2 Vaccine (Vero cell）

    COVID-19

    Enrollment
    1,080
    Start
    May 2021
    Primary Completion
    May 2021
    Completion
    Nov 2021
    NCT04894227
  • Phase 4
    Completed

    Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

    Experimental Group

    COVID-19

    Enrollment
    131,650
    Start
    Jun 2021
    Primary Completion
    Jan 2023
    Completion
    Aug 2023
    NCT04911790
  • Phase 4
    Completed

    Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

    Inactivated COVID-19 Vaccine, 23-valent pneumococcal polysaccharide vaccine

    COVID-19

    Enrollment
    270
    Start
    Jul 2021
    Primary Completion
    Oct 2021
    Completion
    Jan 2022
    NCT04953325
  • Phase 4
    Unknown status

    Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

    SARS-CoV-2 Inactivated Vaccine, The SARS-CoV-2 Inactivated Vaccine

    COVID-19

    Enrollment
    1,400
    Start
    Jun 2021
    Primary Completion
    Aug 2021
    Completion
    Dec 2021est.
    NCT04962308
  • Phase 4
    Completed

    A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine

    Investigational 23-valent PPV, Control 23-valent PPV

    Pneumococcal Infections

    Enrollment
    600
    Start
    Sep 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04989465
  • Phase 4
    Completed

    Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)

    Experimental Group, Control Group

    COVID-19

    Enrollment
    520
    Start
    Nov 2021
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT04993365
  • Phase 4
    Completed

    A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old

    Two doses of quadrivalent influenza vaccine, One dose of quadrivalent influenza vaccine

    Seasonal Influenza

    Enrollment
    600
    Start
    Oct 2021
    Primary Completion
    Oct 2021
    Completion
    Nov 2021
    NCT04997239
  • Phase 4
    Unknown status

    Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19

    High-dosage SARS-CoV-2 vaccine, Medium-dosage SARS-CoV-2 vaccine

    COVID-19

    Enrollment
    1,200
    Start
    Dec 2021
    Primary Completion
    Dec 2021
    Completion
    Jun 2022est.
    NCT05079217

1-25 of 115

Search ClinicalTrials.gov for “Sinovac Biotech”